Nuvation Bio Inc. (NUVB) Earnings History
Net Loss8 years of earnings data (2018–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Nuvation Bio Inc. (NUVB) Earnings Overview
As of June 22, 2026, Nuvation Bio Inc. (NUVB) reported trailing twelve-month net income of -$146M, reflecting +71.6% year-over-year growth. The company earned $-0.39 per diluted share over the past four quarters, with a net profit margin of -325.3%.
Looking at the long-term picture, NUVB's historical earnings data spans multiple years. The company achieved its highest annual net income of -$992,000 in fiscal 2018.
Nuvation Bio Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including KYMR (-$315M net income, -794.4% margin), TPST (-$43M net income), PRAX (-$327M net income), NUVB has outperformed on profitability metrics. Compare NUVB vs KYMR →
NUVB Earnings vs Peers
Earnings metrics vs comparable public companies
NUVB Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$205M | +64.0% | -$213M | $-0.60 | -325.3% | -338.7% |
| 2024 | -$568M | -649.2% | -$593M | $-2.11 | -7213.8% | -7527.3% |
| 2023 | -$76M | +27.3% | -$100M | $-0.35 | - | - |
| 2022 | -$104M | -20.0% | -$120M | $-0.48 | - | - |
| 2021 | -$87M | -108.5% | -$93M | $-0.44 | - | - |
| 2020 | -$42M | -24.2% | -$44M | $-0.19 | - | - |
| 2019 | -$34M | -3282.3% | -$32M | $-0.16 | - | - |
| 2018 | $-992,000 | - | $-992,000 | $-0.01 | - | - |
Download Data
Export NUVB earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NUVB — Frequently Asked Questions
Quick answers to the most common questions about buying NUVB stock.
What is NUVB earnings per share (EPS)?
NUVB trailing twelve-month (TTM) diluted EPS is $-0.39, reflecting +71.6% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2018 to 2025 is available in the table on this page.
What is Nuvation Bio Inc.'s net income?
Nuvation Bio Inc. (NUVB) trailing twelve-month net income is $-146M as of 2025. Earnings grew +71.6% year-over-year.
Is NUVB profitable?
NUVB is not currently profitable on a TTM basis, reporting a net loss of $-146M. Net margin is -325.3%. Investors should monitor for a return to profitability.
What is NUVB's earnings growth rate?
NUVB compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2018 to 2025.
What are NUVB's profit margins?
Nuvation Bio Inc. net profit margin is -325.3%, operating margin is -338.7%, and gross margin is +86.6%. Below-average margins reflect competitive or cost pressures. Return on Equity is -53.2%.
Is NUVB growing earnings?
Yes, NUVB earnings are accelerating — EPS growth of +71.6% exceeds the 5-year CAGR of N/A. TTM net income reached $-146M. Earnings momentum is strengthening.
What was NUVB's best earnings year?
Nuvation Bio Inc.'s highest annual net income on record is $-992000.00, achieved in fiscal year 2018. Earnings history on this page spans 2018 to 2025 and includes all annual and quarterly figures.
What were NUVB's earnings last quarter?
NUVB's most recent reported quarter was Q1 2026. Net income was $5M with diluted EPS of $0.01. For a full breakdown of all quarters, see the quarterly earnings table on this page.